Clinical Phase I Results of GANYMED's iMAB362 Antibody Demonstrate Excellent Safety

06-Aug-2010 - Germany

A clinical first-in-human Phase I multi center study with GANYMED's monoclonal antibody iMAB362 demonstrated excellent safety up to a dosis of 1g/sqm in gastro-esophageal cancer patients. iMAB362 targets GANYMED's proprietary cell surface antigen Claudine 18.2, which is present in 70% of all gastric cancers, 50% pancreatic cancers, 30% esophageal cancers and 25% non small cell lung (NSCL) cancers. In preclinical cancer models iMAB362 demonstrated potent antitumor activity against Claudine 18.2 positive target cells.

"The proven safety and tolerability even at high drug levels confirms GANYMED's concept based on highly cancer specific targets for developing potent antibodies with an excellent safety profile. The Company's anti cancer antibodies are exquisitely positioned to meet current and future needs in solid cancer therapeutics to substantially improve patient care," said Prof. Rolf Krebs, MD, Chairman of the Supervisory Board of GANYMED. "As for iMAB362, this very successful Phase I study paves the way for several Phase II studies in gastro-esophageal and pancreatic cancer."

Other news from the department research and development

Most read news

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous